In the double-blind EPCAT III RCT, aspirin alone was noninferior to 5 days of rivaroxaban followed by aspirin for preventing symptomatic VTE after total hip or knee arthroplasty, with no clinically relevant...
In a multicenter dose de-escalation and expansion study of adults with HIV-related DLBCL, ibrutinib plus R-da-EPOCH showed manageable toxicity and clinical activity, with 3-year event-free and overall...
The FDA approval introduces a nonprescription fixed-dose combination of 2 widely used analgesics for temporary relief of common minor aches and pains in adults and children aged 12 years or older.
A retrospective surveillance study of critical care units at a tertiary care hospital found high CAUTI/UTI and CLABSI rates, with CLABSI rates increasing 2.64-fold during the COVID-19 era.
In two phase 3, double-blind, placebo-controlled trials of adults with noncirrhotic chronic hepatitis B virus infection receiving stable nucleoside or nucleotide analog therapy, 24 weeks of bepirovirsen...
The FDA approved sacituzumab govitecan-hziy (Trodelvy) as monotherapy, and with pembrolizumab-based therapy, for select adults with previously untreated unresectable locally advanced or metastatic...
The FDA approved expanded adjuvant therapy options for adults with renal cell carcinoma with a clear cell component who are at intermediate-high or high risk of recurrence after nephrectomy, with or without...
The FDA approved ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older following contact with an individual with COVID-19.
In the phase 3a REIMAGINE 1 trial, once-weekly cagrilintide–semaglutide reduced HbA1c vs placebo at 40 weeks in adults with early-stage type 2 diabetes that was inadequately controlled with diet and...
